Rouffach

Researchers are investigating the added value of neuroendocrine tests called TRH-ΔΔTSH and DST in predicting how patients with major depression respond to repetitive transcranial magnetic stimulation-theta burst stimulation (rTMS-TBS). This pilot study involves 50 adults aged 18 to 65 who are hospitalized due to major depression and have not adequately responded to two prior antidepressant treatments. The main goal is to see if these tests can predict a clinical response defined as at least a 50% reduction in depression scores after rTMS-TBS treatment. The treatment involves 20 sessions of rTMS-TBS, each lasting 5 minutes and administered daily except on weekends. The theta burst stimulation delivers bursts of magnetic pulses at high frequency targeting brain areas involved in depression. The clinical response is measured after 20 sessions, and some neuroendocrine tests are repeated at the end for participants who showed abnormalities at baseline. Participants will undergo assessments of depression severity using the 17-item Hamilton Depression Scale before treatment, after 10 sessions, and after 20 sessions. An independent psychiatrist blinded to the test results will perform these evaluations. The study includes signing informed consent and verifying eligibility. Researchers will analyze how participants' neuroendocrine test results relate to their clinical response to rTMS-TBS treatment over the course of the study.

People with mental disorders tend to smoke more than the general population, which partly causes significant health differences and shorter life expectancy by 10 to 25 years. This gap is mainly due to heart and lung diseases, including bronchial cancers. Despite their motivation to quit, smoking is often overlooked or tolerated in psychiatric care, making quitting harder due to stronger withdrawal symptoms. This research evaluates a new intervention called "Tabapsy," designed with input from patients, mental health professionals, and general practitioners to support smoking cessation in adults receiving outpatient psychiatric care. The Tabapsy intervention includes a campaign to promote quitting smoking and a structured support program with multiple components: a general information meeting to boost motivation, an assessment workshop to personalize cessation plans, five thematic workshops covering treatments, emotional management, weight control, physical activity, and manual activities, plus peer support groups to encourage mutual help. A dedicated facilitator runs the program in psychiatric medical psychological centers (CMPs), supplemented by a website with resources. The study compares this intervention to usual care practices regarding smoking cessation in a cluster-randomized controlled trial involving psychiatric sectors in France. Participants are regular smokers aged 18 or older who receive outpatient psychiatric care at participating centers. They will complete questionnaires online at the start, and again at 3 and 6 months, covering smoking habits, nicotine dependence, motivation, use of quitting aids, mental and physical well-being, and knowledge about smoking. The main outcome is short-term smoking cessation lasting at least 7 days at 3 months. Secondary goals include assessing cost-effectiveness and how well the intervention is implemented. A total of 6,250 participants will be enrolled over 12 months across 22 sectors.